Hospital Clínico Universitario Lozano Blesa -ko ikertzaileekin lankidetzan egindako argitalpenak (26)

2024

  1. Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial

    The Lancet Infectious Diseases, Vol. 24, Núm. 4, pp. 375-385

  2. Impact of Applying the Global Lung Initiative Criteria for Airway Obstruction in GOLD Defined COPD Cohorts: The BODE and CHAIN Experience

    Archivos de Bronconeumologia, Vol. 60, Núm. 1, pp. 10-15

2022

  1. Comorbidities and mortality risk in adults younger than 50 years of age with chronic obstructive pulmonary disease

    Respiratory Research, Vol. 23, Núm. 1

2021

  1. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia

    Journal of Clinical Investigation, Vol. 131, Núm. 20

2020

  1. International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis

    Liver International, Vol. 40, Núm. 6, pp. 1467-1476

2019

  1. Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

    American Journal of Transplantation, Vol. 18, Núm. 10, pp. 2513-2522

2017

  1. Cardiovascular morbidity and mortality after liver transplantation: The protective role of mycophenolate mofetil

    Liver Transplantation, Vol. 23, Núm. 4, pp. 498-509

  2. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation

    Journal of Hepatology, Vol. 67, Núm. 6, pp. 1168-1176

  3. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection

    Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237

  4. Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study

    Transplant International, Vol. 30, Núm. 10, pp. 1041-1050

  5. Human immunodeficiency virus–infected liver transplant recipients with incidental hepatocellular carcinoma: A prospective multicenter nationwide cohort study

    Liver Transplantation, Vol. 23, Núm. 5, pp. 645-651

  6. Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib

    Oncotarget, Vol. 8, Núm. 61, pp. 103077-103086

  7. Real-world multicenter experience of immunosuppression minimization among 661 liver transplant recipients

    Annals of Transplantation, Vol. 22, pp. 265-275

  8. Reflections on the Implementation of Low-Dose Computed Tomography Screening in Individuals at High Risk of Lung Cancer in Spain

    Archivos de Bronconeumologia, Vol. 53, Núm. 10, pp. 568-573

2016

  1. A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib

    Liver International, Vol. 36, Núm. 8, pp. 1206-1212

  2. Controlling Diabetes after Liver Transplantation: Room for Improvement

    Transplantation, Vol. 100, Núm. 10, pp. e66-e73

  3. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

  4. Recomendaciones SEPAR de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas

    Archivos de Bronconeumologia, Vol. 52, pp. 2-62

  5. Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients

    Transplant Infectious Disease, Vol. 18, Núm. 6, pp. 819-831